PAMper Trial
The PAMper clinical trial is for women who have taken mifepristone (the first tablet) to start a medical abortion, and who have changed their minds and now want to continue their pregnancy.
If you have taken mifepristone, within the last 72 hours and wuold now like to continue your pregnancy instead of proceeding with the abortion, you may be eligible to participate.
If you meet the following criteria and would like more information, see the contact page to get in touch with us via the web form.
Please note that timing is critical and you cannot participate in this study if we cannot provide you with progesterone within 72 hours of taking mifepristone so it is important that you contact us as early as possible if you would like to consider this option.
You must:
- Be less than 72 hours since taking mifepristone (the sooner the better)
- Have not taken misoprostol (the second medication)
- Have no contraindications to progesterone (we will ask you questions about this)
- Be 18 years or older
If you believe you fit this criteria, or you are unsure and would like to find out more, please contact us.
Any questions or concerns may be directed to:
Dr Debbie Garratt, PhD, RN
Trial Coordinator
References
1. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Progesterone support of the luteal phase and in the first trimester. RANZCOG. 2013. C-Obs 29a.
2. Saccone G, Schoen C, Franasiak JM, et al. Supplementation with progestogens in the first trimester of pregnancy to prevent miscarriage in women with unexplained recurrent miscarriage: a systematic review and meta-analysis of randomized, controlled trials. Fertil Steril. 2017;107:430–438 e3.
3. Christian MS, Brent RL, Calda P. Embryo-fetal toxicity signals for 17alpha-hydroxyprogesterone caproate in high-risk pregnancies: a review of the non-clinical literature for embryo-fetal toxicity with progestins. J Matern Fetal Neonatal Med. 2007;20:89–112.
4. Bernard, et al. Continuation of pregnancy after first-trimester exposure to mifepristone: an observational prospective study. BJOG 2013;120:568-74.
5. Delgado, et al. A Case Series Detailing the Successful Reversal of the Effects of Mifepristone Using Progesterone. Issues in Law & Medicine 2018;33:3-13.
6. Davenport, et al. Embryo Survival after Mifepristone: A Systematic Review of the Literature. Issues in Law & Medicine 2017;32:3-18
This project has been approved by the Human Research Ethics Committee of the University of New England:
(Approval No: HE20-101 Valid to: 25/08/2021)